Assessment of MRD at the end of consolidation splits FLT3 wild-type in 2 categories with different prognoses. Patients carrying FLT3 wild-type who achieve an MRD⁻ status have a significantly better OS (A), RFS (B), and CIR (C) than those who remain MRD⁺ (OS, P > .001; RFS and CIR, P < .001). The outcome of FLT3 wild-type MRD⁺ patients is such to replicate the one of those FLT3-ITD⁺.